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Summary. Random-eﬀects meta-analyses are very commonly used in medical statistics. Recent methodological developments
include multivariate (multiple outcomes) and network (multiple treatments) meta-analysis. Here, we provide a new model
and corresponding estimation procedure for multivariate network meta-analysis, so that multiple outcomes and treatments
can be included in a single analysis. Our new multivariate model is a direct extension of a univariate model for network meta-
analysis that has recently been proposed. We allow two types of unknown variance parameters in our model, which represent
between-study heterogeneity and inconsistency. Inconsistency arises when diﬀerent forms of direct and indirect evidence are
not in agreement, even having taken between-study heterogeneity into account. However, the consistency assumption is often
assumed in practice and so we also explain how to ﬁt a reduced model which makes this assumption. Our estimation method
extends several other commonly used methods for meta-analysis, including the method proposed by DerSimonian and Laird
(1986). We investigate the use of our proposed methods in the context of both a simulation study and a real example.
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1. Introduction
Meta-analysis, the statistical process of pooling the results
from separate studies, is commonly used in medical statis-
tics and now requires little introduction. The univariate
random-eﬀects model is often used for this purpose. This
model has recently been extended to the multivariate (multi-
ple outcomes; Jackson et al., 2011) and network (multiple
treatments; Lu and Ades, 2004) meta-analysis settings. In
a network meta-analysis, more than two treatments are
included in the same analysis. The main advantage of network
meta-analysis is that, by using indirect information contained
in the network, more precise and coherent inference is possi-
ble, especially when direct evidence for particular treatment
comparisons is limited. Here, we describe a new model that
extends the random-eﬀects modeling framework to the multi-
variate network meta-analysis setting, so that both multiple
outcomes and multiple treatments may be included in the
same analysis.
Other multivariate extensions of univariate methods for
network meta-analysis have previously been proposed. For
example, Achana et al. (2014) analyze multiple correlated out-
comes in multi-arm studies in public health. Efthimiou et al.
(2014) propose a model for the joint modeling of odds ratios
on multiple endpoints. Efthimiou et al. (2015) develop another
model that is a network extension of an alternative mul-
tivariate meta-analytic model that was originally proposed
by Riley et al. (2008). A network meta-analysis of multiple
outcomes with individual patient data has also been proposed
by Hong et al. (2015) under both contrast-based and arm-
based parameterizations, and Hong et al. (2016) develop a
Bayesian framework for multivariate network meta-analysis.
These multivariate network meta-analysis models are based
on the assumption of consistency in the network, extending
the approach introduced by Lu and Ades (2004). In contrast
to these previously developed methods, the method proposed
here relaxes the consistency assumption. This assumption
is sometimes found to be false across the entire network
(Veroniki et al., 2013). We model the inconsistency using
a design-by-treatment interaction, so that diﬀerent forms of
direct and indirect evidence may not agree, even after tak-
ing between-study heterogeneity into account. However, we
assume that the design-by-interaction terms follow normal
distributions, and so conceptualize inconsistency as another
source of random variation. This allows us to achieve the
dual aim of estimating meaningful treatment eﬀects while also
allowing for inconsistency in the network.
Although we allow inconsistency in the network, we propose
a relatively simple model. Our preference for a simple model
is because the between-study covariance structure is typi-
cally hard to identify accurately in multivariate meta-analyses
(Jackson et al., 2011) and also because network meta-analysis
datasets are usually small (Nikolakopoulou et al., 2014). The
new model that we propose for multivariate network meta
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analysis is a direct generalization of the univariate network
meta-analysis model proposed by Jackson et al. (2016), which
is a particular form of the design-by-treatment interaction
model (Higgins et al., 2012). In addition to proposing a
new model for multivariate network meta-analysis, we also
develop a corresponding new estimation method. This estima-
tion method is based on the method of moments and extends
a wide variety of related methods. In particular, we extend
the estimation method described by DerSimonian and Laird
(1986) by directly extending the matrix based extension of
DerSimonian and Laird’s estimation method for multivariate
meta-analysis (Chen et al., 2012; Jackson et al., 2013). We
adopt the usual two-stage approach to meta-analysis, where
the estimated study-speciﬁc treatment eﬀects (including the
within-study covariance matrices) are computed in the ﬁrst
stage. We give some information about how this ﬁrst stage
is performed but our focus is the second stage, where the
meta-analysis model is ﬁtted.
The article is set out as follows. In Section 2, we brieﬂy
describe the univariate model for network meta-analysis to
motivate our new multivariate network meta-analysis model
in Section 3. We present our new estimation method in Section
4 and we apply our methods to a real dataset in Section 5.
We conclude with a short discussion in Section 6.
2. A Univariate Network Meta-Analysis Model
Here, we describe our univariate modeling framework for net-
work meta-analysis (Jackson et al., 2016; Law et al., 2016).
Without loss of generality, we take treatment A as the ref-
erence treatment for the network meta-analysis. The other
treatments are B, C, etc. We take the design d as referring
only to the set of treatments compared in a study. For exam-
ple, if the ﬁrst design compares treatments A and B only,
then d = 1 refers to two-arm studies that compare these two
treatments. We deﬁne t to be the total number of treatments
included in the network, and td to be the number of treat-
ments included in design d. We deﬁne D to be the number
of diﬀerent designs, Nd to be the number of studies of design
d, and N =
D∑
d=1
Nd to be the total number of studies. We will
use the word “contrast” to refer to a particular treatment
comparison or eﬀect in a particular study, for example, the
“AB contrast” in the ﬁrst study.
We model the estimated relative treatment eﬀects, rather
than the average outcomes in each arm, and so perform con-
trast based analyses. We deﬁne Y di to be the cd × 1 column
vector of estimated relative treatment eﬀects from the ith
study of design d, where cd = td − 1. We deﬁne nd = Ndcd to
be the total number of estimated treatment eﬀects that design
d contributes to the analysis, and n =
D∑
d=1
nd to be the total
number of estimated treatment eﬀects that contribute to the
analysis. To specify the outcome data Y di, we choose a base-
line treatment in each design d. The entries of Y di are then the
estimated eﬀects of the other cd treatments included in design
d relative to this baseline treatment. For example, if we take
d = 2 to indicate the “CDE design” then c2 = 2. Taking C as
the baseline treatment for this design, the two entries of the
Y2i vectors are the estimated relative eﬀects of treatment D
compared to C and of treatment E compared to C. For exam-
ple, the entries of the Y di could be estimated log-odds ratios
or mean diﬀerences.
We use normal approximations for the within-study dis-
tributions. We deﬁne Sdi to be the cd × cd within-study
covariance matrix corresponding to Y di. We treat all Sdi as
ﬁxed and known in analysis. Ignoring the uncertainty in the
Sdi is acceptable provided that the studies are reasonably
large and is conventional in meta-analysis, but this approxi-
mation is motivated by pragmatic considerations because this
greatly simpliﬁes the modeling. We do not impose any con-
straints on the form of Sdi other than they must be valid
covariance matrices. The lead diagonal entries of the Sdi are
within-study variances that can be calculated using standard
methods. Assuming that the studies are composed of inde-
pendent samples for each treatment, the other entries of the
Sdi are calculated as the variance of the average outcome (for
example the log odds or the sample mean) of the baseline
treatment.
We deﬁne δAB1 , δ
AC
1 , · · · , δAZ1 , where Z is the ﬁnal treatment
in the network, to be treatment eﬀects relative to the reference
treatment A, and call them basic parameters (Lu and Ades,
2006). We use the subscript 1 when deﬁning the basic param-
eters to emphasize that they are treatment eﬀects for the
ﬁrst (and in this section, only) outcome. We deﬁne c = t − 1
to be the number of basic parameters in the univariate set-
ting. Treatment eﬀects not involving A can be obtained as
linear combinations of the basic parameters and are referred
to as functional parameters (Lu and Ades, 2006). For exam-
ple, the average treatment eﬀect of treatment E to treatment
C, δCE1 = δAE1 − δAC1 , is a functional parameter. We deﬁne the
c × 1 column vector δ = (δAB1 , δAC1 , · · · , δAZ1 )T and design spe-
ciﬁc cd × c design matrices Z(d). We use the subscript (d) in
these design matrices to emphasis that they apply to each
individual study of design d; we reserve the subscript d for
design matrices that describe regression models for all out-
come data from this design. If the ith entry of the Ydi are
estimated treatment eﬀects of treatment J relative to the ref-
erence treatment A then the ith row of Z(d) contains a single
nonzero entry: 1 in the (j − 1)th column, where j is the posi-
tion of J in the alphabet. If instead the ith entry of theYdi are
estimated treatment eﬀects of treatment J relative to treat-
ment K, K = A, then the ith row of Z(d) contains two nonzero
entries: 1 in the (j − 1)th column and −1 in the (k − 1)th
column.
Our univariate model for network meta-analysis is
Y di = Z(d)δ + di + d + di (1)
where di ∼ N(0, τ2βPcd ), d ∼ N(0, τ2ωPcd ), di ∼ N(0,Sdi),
all di, d , and di are independent, and Pcd is the cd × cd
matrix with ones on the leading diagonal and halves else-
where. We refer to τ2β and τ
2
ω as the between-study variance,
and the inconsistency variance, respectively. The term di is
a study-by-treatment interaction term that models between-
study heterogeneity. The model di ∼ N(0, τ2βPcd ) implies
that the heterogeneity variance is the same for all contrasts
for every study regardless of whether or not the comparison is
relative to the baseline treatment (Lu and Ades, 2004). Other
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simple choices of Pcd , such as allowing the oﬀ-diagonal entries
to diﬀer from 0.5, violate this symmetry between treatments.
For example, in the case d = 2 indicating the CDE design,
the between-study variances for the CD and CE eﬀects in
this study are given by the two diagonal entries of τ2βPcd ,
which are both τ2β . The between-study variance for the eﬀect
of E relative to D is (−1, 1)τ2βPcd (−1, 1)T , which is also τ2β .
The d are design-by-treatment interaction terms that model
inconsistency in the network. The model d ∼ N(0, τ2ωPcd )
implies that the inconsistency variance is the same for all
contrasts for every design; other simple choices of Pcd violate
this symmetry.
To describe all estimates from all studies, we stack the
Y di from the same design to form the nd × 1 column vector
Y d = (YTd1, · · · ,YTdNd )T , and we then stack these Y d to form
the n × 1 column vector Y = (YT1 , · · · ,YTD)T . Jackson et al.
(2016) then use three further matrices that we also deﬁne
here because they will be required to describe the estimation
procedure that follows. The matrix M1 is deﬁned as a n × n
square matrix where m1ij = 0 if the ith and jth entries of Y ,
i, j = 1, · · · n, are estimates from diﬀerent studies; otherwise
m1ii = 1, and m1ij = 1/2 for i = j. The matrix M2 is deﬁned
as a n × n square matrix where m2ij = 0 if the ith and
jth entries of Y , i, j = 1, · · · n, are estimates from diﬀerent
designs; otherwise m2ij = 1 if the ith and jth entries of Y are
estimates of the same treatment comparison (for example,
treatment A compared to treatment B) and m2ij = 1/2 if these
entries are estimates of diﬀerent treatment comparisons. The
supplementary materials show a concrete example showing
how these two matrices are formed. Jackson et al. (2016) also
deﬁne a n × c univariate design matrix Z, where if the ith
entry of Y is an estimated treatment eﬀect of treatment J
relative to the reference treatment A then the ith row of Z
contains a single nonzero entry: 1 in the (j − 1)th column,
where j is the position of J in the alphabet. If instead the
ith entry Y is an estimated treatment eﬀect of treatment
J relative to treatment K, K = A, then the ith row of Z
contains two nonzero entries: 1 in the (j − 1)th column
and −1 in the (k − 1)th column. Deﬁning Sd =
diag(Sd1, · · · ,SdNd ), and then S = diag(S1, · · · ,SD), model
(1) can be presented for the entire dataset as
Y ∼ N(Zδ, τ2βM1 + τ2ωM2 + S).
3. A Multivariate Network Meta-Analysis Model
We now explain how to extend the univariate model in Section
2 to the multivariate setting to handle multiple outcomes. We
deﬁne p to be the number of outcomes, and so the dimension
of the network meta-analysis, so that we now consider the
case where p > 1. The Y di are now pcd × 1 column vectors,
where the Y di contain cd column vectors of length p. For exam-
ple, in a p = 5 dimensional meta-analysis and continuing with
the example where d = 2 indicates the CDE design, we have
c2 = 2. The Y2i are then 10 × 1 column vectors where, taking
C as the baseline treatment for this design, the ﬁrst ﬁve entries
of the Y2i are estimated relative treatment eﬀect of D com-
pared to C and the second ﬁve entries are the same estimate
of E compared to C. We deﬁne the pc × 1 column vector δ =
(δAB1 , δ
AC
1 , . . . , δ
AZ
1 , δ
AB
2 , δ
AC
2 , . . . , δ
AZ
2 , . . . , δ
AB
p , δ
AC
p , . . . , δ
AZ
p )
T , so
that this vector contains the basic parameters for each out-
come in turn. When p = 1 the vector δ reduces to its deﬁnition
in the univariate setting, as given in Section 2.
We deﬁne β and ω to be p × p unstructured covari-
ance matrices that are multivariate generalizations of τ2β and
τ2ω. These two matrices contain the between-study variances
and covariances, and the inconsistency variances and covari-
ances, respectively, for all p outcomes. We refer to β and
ω as the between-study covariance matrix, and the incon-
sistency covariance matrix, respectively. We continue to treat
the within-study covariance matrices Sdi as if ﬁxed and known
in analysis but these are now pcd × pcd matrices. The entries
of the Sdi matrices that describe the covariance of estimated
treatment eﬀects for the same outcome can be obtained as in
the univariate setting. However, the other entries of Sdi, that
describe the covariance between treatment eﬀects for diﬀer-
ent outcomes, are harder to obtain in practice. A variety of
strategies for dealing with this diﬃculty have been proposed
(Jackson et al., 2011; Wei and Higgins, 2013).
3.1. The Proposed Multivariate Model for Network
Meta-Analysis
In the multivariate setting, to allow correlations between
estimated treatment eﬀects for diﬀerent outcomes, both
within studies and designs, we propose that model (1) is
generalized to
Y di = X(d)δ + di + d + di (2)
where X(d) = ((Ip ⊗ Z(d)1)T , · · · , (Ip ⊗ Z(d)cd )T )T , Z(d)i is the
ith row of Z(d), di ∼ N(0,Pcd ⊗ β), d ∼ N(0,Pcd ⊗ ω)
and di ∼ N(0,Sdi), where all di, d , and di are indepen-
dent, and ⊗ is the Kronecker product. The random di
and d continue to model between-study heterogeneity, and
inconsistency, respectively. Recalling that δ contains the basic
parameters for each outcome in turn, the design matrices X(d)
provide the correct linear combinations of basic parameters
to describe the mean of all estimated treatment eﬀects in Y di.
Model (2) reduces to model (1) in one-dimension. The def-
inition of Pcd means that β and ω are the between-study
covariance matrix, and inconsistency covariance matrix, for all
contrasts. We continue deﬁne Y as in the univariate setting,
where Y contains n column vectors of estimated treatment
eﬀects that are of length p, so that Y is a np × 1 column
vector in the multivariate setting. We deﬁne the multivari-
ate np × pc design matrix X = ((Ip ⊗ Z1)T , · · · , (Ip ⊗ Zn)T )T ,
where Zi is the ith row of Z. Model (2) can be presented for
the entire dataset as
Y ∼ N(Xδ,M1 ⊗ β +M2 ⊗ ω + S) (3)
where we continue to deﬁne S as in the univariate case. Matri-
ces M1 and M2 are the same as in the univariate setting,
and so continue to be n × n matrices. Model (3) is a linear
mixed model for network meta-analysis and is conceptually
similar to other models of this type (Piepho et al., 2012).
If ω = 0 then all d = 0 and there is no inconsistency; we
refer to this reduced model as the “consistent model.” If both
β = 0 and ω = 0 then all studies estimate the same eﬀects
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to within-study sampling error and we refer to this model as
the “common-eﬀect and consistent model.”
Missing data (unobserved entries of Y) are common in
applications as not all studies may provide data for all out-
comes and contrasts. When there are missing outcome data,
the model for the observed data is the marginal model for the
observed data implied by (3), where any rows of Y that con-
tain missing values are discarded. We will use a non-likelihood
based approach for making inferences and so assume any data
are missing completely at random (Seaman et al., 2013). We
deﬁne the diagonal np × np missing indicator matrixR, where
Rii = 1 if Yi is observed, Rii = 0 if Yi is missing, and Rij = 0
if i = j.
4. Multivariate Estimation: A New Method of
Moments
Our estimation procedure is motivated by the univariate
method proposed by DerSimonian and Laird (1986). This
was developed in the much simpler setting where each study
provides a single estimate Yi, and where the random-eﬀects
model Yi ∼ N(δ, τ2 + Si) is assumed. This estimation method
for τ2 uses the Q statistic, where Q =∑ S−1i (Yi − δˆ)2 and δˆ =∑
S−1i Yi/
∑
S−1i is the pooled estimate under the common-
eﬀect model (τ2 = 0).
Now consider an alternative representation of this Q statis-
tic. TakingY = (Y1, · · · , Yn)T , S = diag(S1, · · · , Sn), andW =
S−1 means that Q = tr(W(Y− Yˆ)(Y− Yˆ)T ), where Yˆ is
obtained under the common-eﬀect model. To obtain a p × p
matrix generalization of Q for multivariate analyses, we
replace the trace operator with the block trace operator in
this expression (Jackson et al., 2013). The block trace oper-
ator is a generalization of the trace that sums over all n
of the p × p matrices along the main block diagonal of an
np × np matrix. This produces a p × p matrix. In the absence
of missing data we can write our multivariate generalization
of the Q statistic, btr(W(Y− Yˆ)(Y− Yˆ)T ), as a weighted
sum of outer products of p × 1 vectors of residuals under
the common-eﬀect and consistent model. Hence, the distri-
bution of btr(W(Y− Yˆ)(Y− Yˆ)T ) depends directly on the
magnitudes of unknown variance components.
4.1. A Q Matrix for Multivariate Network Meta-Analysis
We deﬁne a within-study precision matrix W corresponding
to S. If there are no missing outcome data in Y then we
deﬁne W = S−1, where S is taken from model (3). If there
are missing data in Y then the entries of W that corre-
spond to observed data are obtained as the inverse of the
corresponding entries of the within-study covariance matrix
of reduced dimension (equal to that of the observed data)
and the other entries of W are set to zero. For example,
consider the case where Y is a 6 × 1 vector but only the
second and ﬁfth entries are observed; this corresponds to
much less outcome data than would be used in practice
but provides an especially simple example. Then we deﬁne
Sr, where the subscript r indicates a dimension reduction,
as a 2 × 2 matrix whose entries are the within-study vari-
ances and covariances of the two observed entries of Y. The
6 × 6 precision matrix W then has all zero entries in the
ﬁrst, third, fourth, and sixth rows and columns. However, the
remaining entries ofW are the entries of the 2 × 2 matrix S−1r ,
so that W22 = (S−1r )11, W25 = (S−1r )12, W52 = (S−1r )21, and
W55 = (S−1r )22. We deﬁne Yˆ to be the ﬁtted value of Y under
the common-eﬀect and consistent model (β = ω = 0), so
that Yˆ = HY where H = X(XTWX)−1XTW. We also deﬁne
an asymmetric np × np matrix (Jackson et al., 2013)
Q = W{R(Y− Yˆ)}{R(Y− Yˆ)}T = W(Y− Yˆ)(Y− Yˆ)TR
(4)
Our deﬁnitions of W and R mean that WR = W, which
results in the simpliﬁed version of Q in (4). From the ﬁrst
form given in (4), we have that the residuals Y− Yˆ are
pre-multiplied by R, so that any residuals that correspond
to missing outcome data do not contribute to Q. Further-
more, missing outcome data do not contribute to Yˆ because
they have no weight under the common-eﬀect and consistent
model. Hence, we can impute missing outcome data with any
ﬁnite value without changing the value of Q. This is merely
a convenient way to handle missing data numerically and has
no implications for the statistical modeling.
4.2. Design Speciﬁc Q Matrices for Multivariate
Network Meta-Analysis
In order to identify the full model, we will require design-
speciﬁc versions of Q that only use data from a particular
design. As in the univariate setting, we stack the outcome
data from design d to form the vectorYd = (YTd1, · · · ,YTdNd )T .
In the multivariate setting, the vector Yd contains nd esti-
mated eﬀects each of length p, so that Yd is now a pnd × 1
column vector. We deﬁne the design speciﬁc nd × nd matrix
Md1 , where m
d
1ij = 0 if the ith and jth estimated eﬀect (of
length p) in Yd , i, j = 1, · · · , nd , are from separate stud-
ies; otherwise md1ii = 1 and md1ij = 1/2 for i = j. We deﬁne
the pnd × pcd design matrix Xd which is obtained by stack-
ing identity matrices of dimension pcd , where we include
one such identity matrix for each study of design d. Hence,
Xd = 1Nd ⊗ Ipcd , where 1Nd is the Nd × 1 column vector where
every entry is one. We also deﬁne the pcd × 1 column vector
βd = X(d)δ + d .
An identiﬁable design-speciﬁc marginal model for outcome
data from design d only, that is implied by model (2), is
Yd ∼ N(Xdβd,Md1 ⊗ β + Sd) (5)
where Sd = diag(Sd1, · · · ,SdNd ). We can also calculate design
speciﬁc versions of (4) where we calculate all quantities,
including the ﬁtted values, using just the data from studies of
design d. We deﬁne these pnd × pnd design speciﬁc matrices
as
Qd = Wd(Yd − Yˆd)(Yd − Yˆd)TRd (6)
where Wd , Rd , and Yˆd in (6) are deﬁned in the same way as
W, R and Yˆ in (4) but where only data from design d are
used. Hence, Rd and Wd are the missing indicator matrix,
and the within-study precision matrix, ofYd , respectively. We
compute Yˆd = HdYd where Hd = Xd(XTdWdXd)−1XTdWd .
When computing Hd we take the matrix inverse to be the
Moore–Penrose pseudoinverse (Searle, 1971). This is so that
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any design-speciﬁc regression corresponding to this hat matrix
that is not fully identiﬁable (due to missing outcome data) can
still contribute to the estimation. We use model (5) to derive
the properties of Qd in equation (6).
4.3. The Estimating Equations
We base our estimation on the two p × p matrices btr(Q)
and
D∑
d=1
btr(Qd), where Q and Qd are given in (4) and (6),
respectively. Speciﬁcally, we match these quantities to their
expectations to estimate the unknown variance parameters
using the method of moments.
4.3.1. Evaluating E[btr(Q)] and deriving the ﬁrst estimat-
ing equation. We deﬁne A = (Inp −H)TW and B = (Inp −
H)TR, which are known np × np matrices. We also divide the
matrices A and B into n2 blocks of p × p matrices, and write
Ai,j and Bi,j, i, j = 1, · · · n, to mean the ith by jth blocks of
A and B respectively. Hence, Ai,j and Bi,j are both p × p
matrices. In the supplementary materials, we show that
E[btr(Q)] =
n∑
i=1
n∑
j=1
n∑
k=1
m1ijAk,iβBj,k
+
n∑
i=1
n∑
j=1
n∑
k=1
m2ijAk,iωBj,k + btr(B).
We apply the vec(·) operator to both sides of the previous
equation and use the identity vec(AXB) = (BT ⊗A)vec(X)
(see Henderson and Searle, 1981), to obtain
vec(E[btr(Q)]) = Cvec(β) +Dvec(ω) +E (7)
where
C =
n∑
i=1
n∑
j=1
n∑
k=1
m1ijB
T
j,k ⊗Ak,i
D =
n∑
i=1
n∑
j=1
n∑
k=1
m2ijB
T
j,k ⊗Ak,i
and
E = vec(btr(B)).
Upon substituting E[btr(Q)] = btr(Q), β = ˆβ and ω = ˆω
in equation (7), the method of moments gives one estimating
equation in the vectorized form of two unknown covariance
matrices.
4.3.2. Evaluating E[btr(Qd)] and deriving the second
estimating equation. Model (5) depends upon one unknown
covariance matrix, β. The intuition is that, upon using all
D of the Qd matrices in (6) and the method of moments
to estimate β, we will then be able to estimate the other
unknown covariance matrix ω using the ﬁrst estimating
equation. We deﬁne design speciﬁc Ad = (Ipnd −Hd)TWd and
Bd = (Ipnd −Hd)TRd , whereAd and Bd are known pnd × pnd
matrices. We also divide the matrices A and B into n2d blocks
of p × p matrices, and write Ad,i,j and Bd,i,j, i, j = 1, · · · , nd ,
to mean the ith by jth blocks of Ad and Bd respectively. In
the supplementary materials we show that
vec
(
E
[ D∑
d=1
btr(Qd)
])
=
(
D∑
d=1
Cd
)
vec(β) +
D∑
d=1
Ed (8)
where
Cd =
nd∑
i=1
nd∑
j=1
nd∑
k=1
md1ijB
T
d,j,k ⊗Ad,k,i
and
Ed = vec(btr(Bd)).
Upon substituting E[
D∑
d=1
btr(Qd)] =
D∑
d=1
btr(Qd) and β = ˆβ
in (8), we obtain a second estimating equation from the
method of moments.
4.4. Solving the Estimating Equations and Performing
Inference
We solve the estimating equation resulting from (8) for
vec(ˆβ) and substitute this estimate into the estimating
equation resulting from (7) and solve for vec(ˆω).
4.4.1. Estimating Σβ under the consistent model. Some
applied analysts may prefer to assume the consistent model
(ω = 0). As in the univariate case (Jackson et al., 2016), we
have two possible ways of estimating β under the consistent
model: we can use the estimating equation resulting from (7)
with ω = 0 or the estimating equation resulting from (8) as
in the full model. Also as in the univariate case, we suggest
the former option because it uses the information made by
assuming consistency when estimating β. However, this ﬁrst
option is valid only under the consistent model.
4.4.2. “Truncating” the estimates of the unknown
covariance matrices so that they are symmetric and pos-
itive semi-deﬁnite. As in the univariate case, there is
the problem that the point estimates of the two unknown
covariance matrices are not necessarily positive semi-deﬁnite.
The method of moments does not even initially enforce
the constraint that the point estimates of the unknown
covariance matrices are symmetrical (Chen et al., 2012;
Jackson et al., 2013). We produce symmetric estimators
corresponding to an estimated covariance matrix of ˆ as
(ˆT + ˆ)/2 (Chen et al., 2012; Jackson et al., 2013). This also
corresponds to taking the average of estimates that result
from our Q and Qd matrices and their transposes (Jackson
et al., 2013). We then write these symmetric estimators in
terms of their spectral decomposition (Chen et al., 2012;
Jackson et al., 2013) and truncate any negative eigenvalues
to zero to provide the ﬁnal symmetric positive semi-deﬁnite
estimated covariance matrices. Speciﬁcally, we deﬁne the
truncated estimate corresponding to the symmetrical ˆ as
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ˆ
+ =
p∑
i=1
max(0, λi)eie
T
i , where λi is the ith eigenvalue of
the symmetric ˆ and ei is the corresponding normalized
eigenvector.
4.4.3. Inference for δ. Inference for δ then proceeds as
a weighted regression where all weights are treated as ﬁxed
and known. Writing Vˆ as the estimated variance of Y in
(3), in the absence of missing outcome data we have δˆ =
(XT Vˆ−1X)−1XT Vˆ−1Y where Var(δˆ) = (XT Vˆ−1X)−1. In the
presence of missing data we can, under our missing com-
pletely at random assumption, apply these standard formulae
for weighted regression to the observed outcomes. Alterna-
tively and equivalently, we can impute the missing outcome
data in Y with an arbitrary value and replace Vˆ−1 with the
precision matrix corresponding to Vˆ, calculated in the way
explained for S in Section 4.1 (Jackson et al., 2011). Approx-
imate conﬁdence intervals and hypothesis tests for all basic
parameters for all outcomes then immediately follow by tak-
ing δˆ to be approximately normally distributed. Inferences
for functional parameters follow by taking appropriate linear
combinations of δˆ.
4.5. Special Cases of the Estimation Procedure
In the supplementary materials, we show that the pro-
posed method reduces to two previous methods in special
cases. If all studies are two arm studies and consistency is
assumed then the proposed method reduces to the matrix
based method for multivariate meta-regression (Jackson
et al., 2013). The proposed multivariate method reduces to
the univariate DerSimonian and Laird method for network
meta-analysis (Jackson et al., 2016) when p = 1.
4.6. Model Identiﬁcation
If the necessary standard matrix inversions resulting from the
estimating equations from (7) and (8) cannot be performed
then both unknown variance components cannot be identiﬁed
using the proposed method. A minimum requirement for any
multivariate modeling is that the common-eﬀect and consis-
tent model must be identiﬁable. This means that there must
be some information (direct or indirect) about each basic
parameter for all outcomes. Two or more studies of the same
design must provide data for all possible pairs of outcomes to
identify β. Two or more studies of diﬀerent designs must
provide data for all possible pairs of outcomes to identify
ω. If these conditions are satisﬁed then the model will be
identiﬁable. In situations where our model is not identiﬁable
we suggest that simpler models should be considered instead.
Possible strategies for this include considering models of lower
dimension or the consistent model. In practice, it is highly
desirable to have more than the minimum amount of replica-
tion required, both within and between designs, so that the
model is well identiﬁed. We make some pragmatic decisions
in the next section for our example to provide suﬃcient repli-
cation within designs, in order to estimate β with reasonable
precision.
5. Example
The methodology developed in this article is now applied to an
illustrative example in relapsing remitting multiple sclerosis
(RRMS). Multiple sclerosis (MS) is an inﬂammatory disease
of the brain and spinal cord and RRMS is a common type
of MS. The eﬀectiveness of a new treatment is typically mea-
sured to assess its impact on relapse rate and odds of disease
progression. Magnetic Resonance Imaging (MRI) allows mea-
surement of the number of new or enlarging lesions in the
brain. Three outcomes are included in our analyses, so that
p = 3 in the full three-dimensional network meta-analysis.
These three outcomes are: (i) the log rate ratio of new or
enlarging MRI lesions; (ii) the log annualized relapse rate
ratio; and (iii) log disability progression odds ratio. Relapse
is deﬁned as appearance of new, worsening or recurrence
of neurological symptoms that can be attributable to MS,
accompanied by an increase of a score on the Expanded
Disability Status Scale (EDSS) and also functional-systems
score(s), lasting at least 24 hours, preceded by neurologic sta-
bility for at least 30 days. Disability progression is deﬁned as
an increase in EDSS score that was sustained for 12 weeks,
with an absence of relapse at the time of assessment. Negative
basic parameters indicate that treatments B-F are beneﬁcial
compared to treatment A throughout.
Data in this illustrative example were obtained from
ten randomized controlled trials of six treatment options
Table 1
Summary of the relapsing remitting multiple sclerosis dataset.
Study Design Outcomes
IFNB SG (1) AB All three outcomes measured
IFNB SG (2) AB All three outcomes measured
Jacobs/Simon AC All three outcomes measured
PRISMS (1) AC All three outcomes measured
PRISMS (2) AC All three outcomes measured
Johnson AD Relapse rate and disability progression only
Durelli BC Relapse rate and disability progression only
O’Connor (1) BD Relapse rate and disability progression only
O’Connor (2) BD Relapse rate and disability progression only
Mikol CD All three outcomes measured
FREEDOMS 1 AEF All three outcomes measured
FREEDOMS 2 AEF All three outcomes measured
TRANSFORMS CEF All three outcomes measured
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Figure 1. Network diagram for RRMS dataset. A –
placebo, B – interferon beta-1b, C – interferon beta-1a,
D – glatiramer, E – ﬁngolimod 0.5mg, F – ﬁngolimod 1.25mg.
Left-hand-side network corresponds to studies reporting the
log annualized relapse rate ratio and log disability progres-
sion odds ratio (y2 and y3) for which data are complete.
The right-hand-side network corresponds to studies report-
ing the log rate ratio of new or enlarging MRI lesions (y1
which is not reported in four studies). The numbers shown
on the network edges are the number of direct comparisons
of each pair of treatments; the absence of an edge indicates
that there is no direct comparison. Three of the thirteen
studies are three arm trials which are each taken to pro-
vide three direct comparisons (a direct comparison between
each treatment pair). Hence, there are 19 direct compar-
isons in the left-hand-side network where there is no missing
data.
(coded in the network data as treatments A–F); placebo (A),
interferon beta-1b (B), interferon beta-1a (C), glatiramer (D),
and two doses of ﬁngolimod; 0.5mg (E) and 1.25mg (F).
Three trials of ﬁngolimod were three-arm (two doses and a
control) and are included as three-arm studies. Three trials
of interferon beta (one 1a and two 1b) were three-arm (also
two doses and a control), and these were included as separate
two-arm trials (each dose against the control, with the number
of participants in each control arm halved). This ignores the
diﬀerences in doses of interferon beta and was a pragmatic
decision to help provide an identiﬁable network. Brieﬂy, in
this example there is very little replication within designs,
so that identifying β well is very diﬃcult without making
pragmatic decisions such as this. Sormani et al. (2010) also
treat these particular studies as two separate studies in this
way, which helps them to identify their meta-regression mod-
els. Treating these three studies as separate two-arm trials
means that the data are analyzed as being from thirteen stud-
ies and a summary of the resulting data structure is shown in
Table 1. There are eight diﬀerent designs in Table 1 and so
there is relatively little replication within designs, even when
including three of the three-arm studies as separate two arm
studies. Full details of the dataset that are relevant to this
article are described in the supplementary materials and see
also Bujkiewicz et al. (2016). Figure 1 provides network dia-
grams that show the number of comparisons between each
pair of treatments on the edges. In these diagrams, the three
arm studies (Table 1) are taken to contribute three compar-
isons, for example, the CEF study contributes CE, CF, and
EF comparisons. Two estimates of treatment eﬀect from this
study contribute to analyses however because C is taken as
the baseline; the study’s estimated EF treatment eﬀect con-
tains no additional information once its CE and CF contrasts
are included in the analysis.
Table 2
Treatment eﬀect estimates of each treatment relative to the reference treatment A (placebo).
Estimate (se)
Model AB AC AD AE AF
MRI (y1)
Univariate (y1) −0.95 (0.39) −1.00 (0.21) −0.68 (0.50) −1.38 (0.26) −1.52 (0.26)
Bivariate (y1, y2) −0.94 (0.39) −1.00 (0.21) −0.68 (0.50) −1.39 (0.26) −1.53 (0.26)
Bivariate (y1, y3) −0.96 (0.39) −0.98 (0.22) −0.66 (0.50) −1.38 (0.26) −1.51 (0.26)
trivariate (y1, y2, y3) −0.96 (0.39) −0.97 (0.22) −0.67 (0.50) −1.38 (0.26) −1.51 (0.26)
Relapse rate (y2)
Univariate (y2) −0.35 (0.10) −0.25 (0.09) −0.34 (0.11) −0.81 (0.12) −0.78 (0.12)
Bivariate (y1, y2) −0.35 (0.10) −0.25 (0.09) −0.34 (0.11) −0.81 (0.12) −0.78 (0.12)
Bivariate (y2, y3) −0.36 (0.11) −0.23 (0.10) −0.33 (0.12) −0.80 (0.13) −0.77 (0.13)
trivariate (y1, y2, y3) −0.36 (0.11) −0.23 (0.10) −0.33 (0.12) −0.80 (0.13) −0.77 (0.13)
Disability progression (y3)
Univariate (y3) −0.46 (0.25) −0.11 (0.21) −0.42 (0.25) −0.33 (0.25) −0.37 (0.24)
Bivariate (y2, y3) −0.47 (0.25) −0.10 (0.21) −0.43 (0.25) −0.37 (0.25) −0.37 (0.25)
Bivariate (y1, y3) −0.46 (0.25) −0.11 (0.21) −0.42 (0.25) −0.34 (0.25) −0.38 (0.25)
Trivariate (y1, y2, y3) −0.47 (0.25) −0.10 (0.21) −0.43 (0.25) −0.37 (0.25) −0.37 (0.25)
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Table 3
Inconsistency and heterogeneity covariance matrices estimates.
Model ω11 ω12 ω13 ω22 ω23 ω33
Univariate (y1) 0.0000
Univariate (y2) 0.0115
Univariate (y3) 0.0713
Bivariate (y1, y2) 0.0002 0.0017 0.0125
Bivariate (y1, y3) 0.0018 0.0116 0.0741
Bivariate (y2, y3) 0.0161 0.0344 0.0735
Trivariate (y1, y2, y3) 0.0027 0.0066 0.0143 0.0161 0.0349 0.0756
β11 β12 β13 β22 β23 β33
Univariate (y1) 0.1508
Univariate (y2) 0.0043
Univariate (y3) 0.0000
Bivariate (y1, y2) 0.1523 −0.0110 0.0047
Bivariate (y1, y3) 0.1526 −0.0191 0.0024
Bivariate (y2, y3) 0.0061 0.0015 0.0004
Trivariate (y1, y2, y3) 0.1538 −0.0116 −0.0195 0.0059 0.0024 0.0027
Table 2 shows the estimates of the basic parameters (treat-
ment eﬀects relative to the reference treatment, placebo)
obtained from univariate network meta-analyses, bivariate
analyses for all three combinations of pairs of outcomes and
the trivariate analysis. The results are similar across all analy-
ses, and conclusions from univariate and multivariate analyses
are the same. This is disappointing because multivariate anal-
yses have not resulted in more precise inference. The entries
of ˆβ and ˆω are shown in Table 3. The positive estimates
obtained for the unknown variance components suggest that
this example exhibits some between-study heterogeneity and
inconsistency. In order to assess the impact of the unknown
variance components, we also ﬁtted the consistent model and
the common-eﬀect and consistent model (results not shown)
using all three outcomes (p = 3). On average, the standard
errors of the ﬁfteen basic parameters from the full model are
35% greater (range: 13–84%) than those from the consistent
model, which in turn are 58% (range: 8–128%) greater than
those from the common-eﬀect and consistent model. Both the
between-study heterogeneity and inconsistency have notable
impact.
The multivariate analysis adds to the univariate analyses
in two main ways. Firstly, the ﬁnding that the multivariate
analysis is in good agreement with the univariate analyses
is a particularly important ﬁnding for treatment eﬀects on
MRI where a substantial proportion of data were missing.
It has been demonstrated by Kirkham et al. (2012) that a
multivariate approach to meta-analysis can help obtain more
accurate estimates in the presence of outcome reporting bias.
Hence, the multivariate analysis reduces concerns that this
univariate analysis is aﬀected by reporting bias. Secondly joint
inferences for all three outcomes are possible under the mul-
tivariate model. For example, and as we might anticipate, in
our example the estimated log annualized relapse rate ratios
and log disability progression odds ratios are highly positively
correlated; from Var(δˆ) in our three-dimensional multivari-
ate meta-analysis, the correlations between the ﬁve pairs of
estimated basic parameters for these two outcomes are all
between 0.63 and 0.75. Medical decision making based jointly
on these two outcomes should take this high positive cor-
relation into account, and this is only possible by using a
multivariate approach. For example, a formal decision anal-
ysis involving these two outcomes should be based on their
joint distribution rather than their two marginal distributions.
In the supplementary materials, we perform a simulation
study to further explore how the proposed methodology
performs.
6. Discussion
We have proposed a new model for dealing with both
multiple treatment contrasts and multiple outcomes, to
provide a framework for conducting multivariate network
meta-analysis. By using a matrix-based method of moments
estimator, our methodology naturally builds on previous work
(such as the well-known DerSimonian and Laird approach)
and is computationally very fast, relative to other poten-
tial estimation approaches such as REML or MCMC; this is
especially the case in very high dimensions and so our method-
ology is particularly advantageous for ambitious analyses of
this type. The main disadvantage is that, as a necessary conse-
quence of its semi-parametric nature, the method of moments
is not based on suﬃcient statistics and so is not fully eﬃ-
cient. The loss in eﬃciency relative to maximum likelihood
estimation awaits investigation but we anticipate that this
will be less serious for inferences about the average eﬀects
than the unknown variance components. Furthermore, the
within-study normal approximations used in our model are
not necessarily very accurate even in moderately sized studies.
Since our analysis uses a general design matrix, the model-
ing may easily be extended by adding study level covariates
to describe and ﬁt multivariate network meta-regressions.
In the network meta-analysis setting, these regressions have
the potential to explain the reasons for inconsistency and
model multiple dose level responses. Our method of moments
estimation can be combined with approaches that “inﬂate”
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conﬁdence intervals from a frequentist random eﬀects meta-
analysis (Hartung and Knapp, 2001; Jackson and Riley, 2014).
In conclusion, we have developed a new model and estima-
tion method for multivariate network meta-analysis, which
can describe multiple treatments and multiple correlated out-
comes. An R function is available in the web supplementary
materials that implements the proposed methodology.
7. Supplementary Materials
Web appendices referenced in Sections 2, 4, and 5 are available
with this article at the Biometrics website on Wiley Online
Library. Computing codes are also available.
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